Irina Vladimirovna Poddubnaya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Irina Vladimirovna Poddubnaya has a total of 377 co-authors. Here are the top co-authors by number of shared publications:
- Lali Galimovna Babicheva
Russian Medical Academy of Continuous Professional Education
11 shared publications - Irina Vladimirovna Kolyadina
Russian Medical Academy of Continuous Professional Education
10 shared publications - Ivan Sokratovich Stilidi
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
8 shared publications - Svetlana Vasilievna Chulkova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
8 shared publications - Elena N. Sholokhova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
7 shared publications - Nikolay Alexeevich Ognerubov
Russian Medical Academy of Continuous Professional Education
7 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (4) , 363-374
Obinutuzumab-Based Regimens in the First-Line Therapy for Follicular Lymphoma: Data from Real-World Clinical Practice in 41 Medical Institutions
AIM. To assess the efficacy and safety of combined obinutuzumab-based regimens in the first-line therapy for follicular lymphoma (FL) in real-world clinical practice. MATERIALS & METHODS. This retrospective multicenter study enrolled 279 newly diagnosed FL patients treated with obinutuzumab in combination with chemotherapy at 41 medical institutions in Russia from 2018 to 2026. The median age of patients was 49.2 years (range 30–83 years), 60.6 % of them were women. Obinutuzumab-based regimens were predominantly administered to patients with stage III/IV (86.4 %), advanced tumor spread (60.2 %), and often with intraabdominal location (76.3 %). More than 1/3 of patients had extranodal lesions (41.9 %) and bulky tumors (34.8 %). According to FLIPI score, there were 74.9 % of patients with intermediate and poor prognosis. More than half of the patients (54.4 %) received anthracycline-based G-CHOP regimen as initial therapy, GB was administered to 30.1 % of patients. Maintenance therapy with obinutuzumab was used in 72.8 % of cases. RESULTS. Overall response to therapy was achieved in 95.6 % of patients, the rate of complete metabolic response was 91.1 %. Adverse events of any grade were observed in 51.8 % of patients, grade ≥ 3 was identified in 29 % (primarily neutropenia and infectious complications). With the median follow-up of 16.3 months, disease progression or relapse were diagnosed in 21 (7.5 %) patients, histological transformation into diffuse large B-cell lymphoma was reported after 6 out of 14 biopsies performed at the stage of FL relapse. The 2-year progression-free survival was 89.6 %, and the 2-year overall survival was 98 %. CONCLUSION. The results of this study confirm high efficacy of obinutuzumab in the first-line therapy for FL patients with prognostically unfavorable characteristics of tumor. Overall and complete metabolic response rates are consistent with the international data. The administration of obinutuzumab-based regimens provide significant therapeutic control of the disease and confirm the reproducibility of the data from clinical studies in real-world healthcare practice.
- 1 October 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (4) , 363-374
Open AccessObinutuzumab-Based Regimens in the First-Line Therapy for Follicular Lymphoma: Data from Real-World Clinical Practice in 41 Medical Institutions
AIM. To assess the efficacy and safety of combined obinutuzumab-based regimens in the first-line therapy for follicular lymphoma (FL) in real-world clinical practice. MATERIALS & METHODS. This retrospective multicenter study enrolled 279 newly diagnosed FL patients treated with obinutuzumab in combination with chemotherapy at 41 medical institutions in Russia from 2018 to 2026. The median age of patients was 49.2 years (range 30–83 years), 60.6 % of them were women. Obinutuzumab-based regimens were predominantly administered to patients with stage III/IV (86.4 %), advanced tumor spread (60.2 %), and often with intraabdominal location (76.3 %). More than 1/3 of patients had extranodal lesions (41.9 %) and bulky tumors (34.8 %). According to FLIPI score, there were 74.9 % of patients with intermediate and poor prognosis. More than half of the patients (54.4 %) received anthracycline-based G-CHOP regimen as initial therapy, GB was administered to 30.1 % of patients. Maintenance therapy with obinutuzumab was used in 72.8 % of cases. RESULTS. Overall response to therapy was achieved in 95.6 % of patients, the rate of complete metabolic response was 91.1 %. Adverse events of any grade were observed in 51.8 % of patients, grade ≥ 3 was identified in 29 % (primarily neutropenia and infectious complications). With the median follow-up of 16.3 months, disease progression or relapse were diagnosed in 21 (7.5 %) patients, histological transformation into diffuse large B-cell lymphoma was reported after 6 out of 14 biopsies performed at the stage of FL relapse. The 2-year progression-free survival was 89.6 %, and the 2-year overall survival was 98 %. CONCLUSION. The results of this study confirm high efficacy of obinutuzumab in the first-line therapy for FL patients with prognostically unfavorable characteristics of tumor. Overall and complete metabolic response rates are consistent with the international data. The administration of obinutuzumab-based regimens provide significant therapeutic control of the disease and confirm the reproducibility of the data from clinical studies in real-world healthcare practice.
- Open Access
- 29 July 2026
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 28 (2) , 106-119
The principle of "discretion" and its application in oncology during surgical treatment in accordance with clinical guidelines: law enforcement practice
Background. This article presents a thorough medical and legal examination of the principle of "discretion" in the surgical management of malignancies. The significance of this study arises from the mandatory implementation of clinical guidelines effective January 1, 2022, in accordance with Article 37 of Federal Law No. 323-ФЗ. This legislation has notably restricted the scope for individualized medical decision-making. At the same time, the complete algorithmization of surgical oncology remains fundamentally impossible due to the unique features of each clinical case. The authors interpret medical discretion as a specific form of administrative discretion – a legally conferred right enabling physicians to make informed and independent decisions based on clinical circumstances, evidence-based data, and the overarching principle of safeguarding the patient's health. Aim. To provide a comprehensive medical and legal analysis of the "discretion" principle within the surgical phase of cancer treatment, including examining its legal boundaries, its relationship with clinical guidelines, and the notion of informed voluntary consent, as well as an assessment of relevant law enforcement practices. Materials and methods. The study used system analysis, formal legal analysis, comparative law, and content analysis of judicial rulings. A total of 87 judicial decisions about civil cases from 2018 to 2025, relevant regulatory frameworks, and clinical guidelines issued by the Ministry of Health of Russia, the Association of Oncologists of Russia, the Russian Society of Clinical Oncology (RUSSCO), as well as NCCN and ESMO guidelines, along with the 8th edition of the TNM classification of malignant tumors, were reviewed. Results. The findings indicate that discrepancies in clinical and pathomorphological staging, which may reach up to 23.9% in colorectal cancer, render intraoperative approach adjustments a necessary practice. Analysis of specific court cases revealed that the legitimacy of extending the surgical intervention is evaluated not by the outcome but by the appropriateness of the surgeon's actions at the time they were performed, based on the intrinsic connection between surgical practices and pathological morphology, thereby facilitating a clear distinction in responsibility between surgery and pathology teams. Particular importance is attached to informed voluntary consent; it is the substance and completeness of this consent – rather than the mere availability of the document itself – that serves as the decisive mechanism for risk allocation. Conclusion. The authors establish criteria for the legality of extending the surgical intervention and advocate for enhancements to clinical guidelines, the format of informed voluntary consent, surgical protocols, the introduction of a standard for the "reasonable surgeon," and the legislative endorsement of the concept of "reasonable medical risk."
- 29 July 2026
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 28 (2) , 106-119
Open AccessThe principle of "discretion" and its application in oncology during surgical treatment in accordance with clinical guidelines: law enforcement practice
Background. This article presents a thorough medical and legal examination of the principle of "discretion" in the surgical management of malignancies. The significance of this study arises from the mandatory implementation of clinical guidelines effective January 1, 2022, in accordance with Article 37 of Federal Law No. 323-ФЗ. This legislation has notably restricted the scope for individualized medical decision-making. At the same time, the complete algorithmization of surgical oncology remains fundamentally impossible due to the unique features of each clinical case. The authors interpret medical discretion as a specific form of administrative discretion – a legally conferred right enabling physicians to make informed and independent decisions based on clinical circumstances, evidence-based data, and the overarching principle of safeguarding the patient's health. Aim. To provide a comprehensive medical and legal analysis of the "discretion" principle within the surgical phase of cancer treatment, including examining its legal boundaries, its relationship with clinical guidelines, and the notion of informed voluntary consent, as well as an assessment of relevant law enforcement practices. Materials and methods. The study used system analysis, formal legal analysis, comparative law, and content analysis of judicial rulings. A total of 87 judicial decisions about civil cases from 2018 to 2025, relevant regulatory frameworks, and clinical guidelines issued by the Ministry of Health of Russia, the Association of Oncologists of Russia, the Russian Society of Clinical Oncology (RUSSCO), as well as NCCN and ESMO guidelines, along with the 8th edition of the TNM classification of malignant tumors, were reviewed. Results. The findings indicate that discrepancies in clinical and pathomorphological staging, which may reach up to 23.9% in colorectal cancer, render intraoperative approach adjustments a necessary practice. Analysis of specific court cases revealed that the legitimacy of extending the surgical intervention is evaluated not by the outcome but by the appropriateness of the surgeon's actions at the time they were performed, based on the intrinsic connection between surgical practices and pathological morphology, thereby facilitating a clear distinction in responsibility between surgery and pathology teams. Particular importance is attached to informed voluntary consent; it is the substance and completeness of this consent – rather than the mere availability of the document itself – that serves as the decisive mechanism for risk allocation. Conclusion. The authors establish criteria for the legality of extending the surgical intervention and advocate for enhancements to clinical guidelines, the format of informed voluntary consent, surgical protocols, the introduction of a standard for the "reasonable surgeon," and the legislative endorsement of the concept of "reasonable medical risk."
- Open Access
- 29 July 2026
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 28 (2) , 96-103
10 cases and 10 solutions from Russian practice: from first-line to rescue therapy. Poster of the 37th Lymphorum with comprehensive debriefings and expert commentaries
On May 15, 2026, Moscow hosted the 37th Lymphorum Interactive Expert Forum, which focused on contemporary approaches to the diagnosis and treatment of lymphoproliferative diseases. The interactive format of this event included the analysis of challenging clinical cases in collaboration with clinicians, pathomorphologists, and clinical experts. This review presents an analysis of 10 clinical cases presented during the forum sessions, along with insights from pertinent studies that underpin current pharmacological strategies for patients with lymphoproliferative diseases. Such scientific events underscore the importance of collaborative efforts among specialists from diverse fields to enhance treatment outcomes and improve the quality of life for patients with oncohematological diseases.
- 29 July 2026
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 28 (2) , 96-103
Open Access10 cases and 10 solutions from Russian practice: from first-line to rescue therapy. Poster of the 37th Lymphorum with comprehensive debriefings and expert commentaries
On May 15, 2026, Moscow hosted the 37th Lymphorum Interactive Expert Forum, which focused on contemporary approaches to the diagnosis and treatment of lymphoproliferative diseases. The interactive format of this event included the analysis of challenging clinical cases in collaboration with clinicians, pathomorphologists, and clinical experts. This review presents an analysis of 10 clinical cases presented during the forum sessions, along with insights from pertinent studies that underpin current pharmacological strategies for patients with lymphoproliferative diseases. Such scientific events underscore the importance of collaborative efforts among specialists from diverse fields to enhance treatment outcomes and improve the quality of life for patients with oncohematological diseases.
- Open Access
- 1 July 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (3)
Pola-R-CHP Regimen as First-Line Therapy for Diffuse Large B-Cell Lymphoma: A Retrospective Study of Real-World Clinical Practice
BACKGROUND. For more than 20 years, the standard first-line therapy for diffuse large B-cell lymphoma (DLBCL) has been the R-CHOP regimen. However, about 30–40 % of patients experience relapsed/refractory disease. In the randomized POLARIX study, polatuzumab vedotin-based regimen (Pola-R-CHP) demonstrated a significant progression-free survival advantage over the standard R-CHOP. Yet, the evidence on the use of Pola-R-CHP in the real-world clinical practice in the Russian Federation is currently missing. AIM. To assess the efficacy and safety of the Pola-R-CHP regimen in patients with newly diagnosed DLBCL in a real-world setting in the Russian Federation. MATERIALS & METHODS. The multi-center retrospective study enrolled the data from 84 patients (48 men and 36 women) with immunomorphologically verified DLBCL diagnosis treated with polatuzumab vedotin-based first line therapy at 30 medical institutions of the Russian Federation in the period of 2022–2026. The median age of patients was 63 years (range 22–87 years). In 88 % of patients, DLBCL grade 3–4 was reported, 86 % belonged to a high-risk (IPI ≥ 3) group. The primary endpoint was complete response (CR) and overall response (OR) rate after 6 therapy cycles. Secondary endpoints included overall survival (OS), progression-free survival (PFS), metabolic response reported by PET/CT, and the analysis of safety profile. RESULTS. Full treatment was completed by 68 (81 %) out of 84 patients. After treatment, CR was 80.9 % and OR was 95.0 %. By PET/CT, complete metabolic response was achieved in 47/60 (78 %) patients. The median follow-up was 15.5 months. Neither median PFS nor median OS were achieved; the 2-year PFS was 82.5 % and the 2-year OS was 85.0 %. Most common adverse events (AEs) of any grade were neutropenia (67 %), leukopenia (55 %), anemia (35 %), and febrile neutropenia (14 %). AEs ≥ grade 3 were reported in 31 % of patients. CONCLUSION. In the real-world clinical practice in the Russian Federation, the Pola-R-CHP regimen showed high efficacy and favorable safety profile in the first-line therapy for DLBCL, also in the population of high-progression-risk patients. The results of the study are consistent with international data and prove the feasibility of risk-adapted treatment for DLBCL.
- 1 July 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (3)
Open AccessPola-R-CHP Regimen as First-Line Therapy for Diffuse Large B-Cell Lymphoma: A Retrospective Study of Real-World Clinical Practice
BACKGROUND. For more than 20 years, the standard first-line therapy for diffuse large B-cell lymphoma (DLBCL) has been the R-CHOP regimen. However, about 30–40 % of patients experience relapsed/refractory disease. In the randomized POLARIX study, polatuzumab vedotin-based regimen (Pola-R-CHP) demonstrated a significant progression-free survival advantage over the standard R-CHOP. Yet, the evidence on the use of Pola-R-CHP in the real-world clinical practice in the Russian Federation is currently missing. AIM. To assess the efficacy and safety of the Pola-R-CHP regimen in patients with newly diagnosed DLBCL in a real-world setting in the Russian Federation. MATERIALS & METHODS. The multi-center retrospective study enrolled the data from 84 patients (48 men and 36 women) with immunomorphologically verified DLBCL diagnosis treated with polatuzumab vedotin-based first line therapy at 30 medical institutions of the Russian Federation in the period of 2022–2026. The median age of patients was 63 years (range 22–87 years). In 88 % of patients, DLBCL grade 3–4 was reported, 86 % belonged to a high-risk (IPI ≥ 3) group. The primary endpoint was complete response (CR) and overall response (OR) rate after 6 therapy cycles. Secondary endpoints included overall survival (OS), progression-free survival (PFS), metabolic response reported by PET/CT, and the analysis of safety profile. RESULTS. Full treatment was completed by 68 (81 %) out of 84 patients. After treatment, CR was 80.9 % and OR was 95.0 %. By PET/CT, complete metabolic response was achieved in 47/60 (78 %) patients. The median follow-up was 15.5 months. Neither median PFS nor median OS were achieved; the 2-year PFS was 82.5 % and the 2-year OS was 85.0 %. Most common adverse events (AEs) of any grade were neutropenia (67 %), leukopenia (55 %), anemia (35 %), and febrile neutropenia (14 %). AEs ≥ grade 3 were reported in 31 % of patients. CONCLUSION. In the real-world clinical practice in the Russian Federation, the Pola-R-CHP regimen showed high efficacy and favorable safety profile in the first-line therapy for DLBCL, also in the population of high-progression-risk patients. The results of the study are consistent with international data and prove the feasibility of risk-adapted treatment for DLBCL.
- Open Access
- 20 January 2026
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 21 (4) , 71-84
From clinical trials to routine practice: 7-year results of the monarchE randomized clinical trial and experience with the use of abemaciclib in hormone-dependent, HER2-negative, high-risk, early breast cancer
The 7-year results of the monarchE randomized clinical trial of adjuvant endocrine therapy escalation with abemaciclib in patients with hormone-dependent, HER2-negative, high-risk, early breast cancer. Three-year experience with the use of abemaciclib in 64 patients with hormone-dependent, HER2-negative, early breast cancer in real-world practice is analyzed, and the criteria for selecting combination endocrine therapy and the safety profile of treatment escalation are assessed. An indirect comparison of data from the Russian analysis and the randomized clinical monarchE trial of adjuvant endocrine therapy escalation in patients with a high risk of recurrence is conducted. Clinical cases of abemaciclib use in routine practice in Russian patients are presented.
- 20 January 2026
- Published by Publishing House ABV Press in Tumors of female reproductive system
- Vol. 21 (4) , 71-84
Open AccessFrom clinical trials to routine practice: 7-year results of the monarchE randomized clinical trial and experience with the use of abemaciclib in hormone-dependent, HER2-negative, high-risk, early breast cancer
The 7-year results of the monarchE randomized clinical trial of adjuvant endocrine therapy escalation with abemaciclib in patients with hormone-dependent, HER2-negative, high-risk, early breast cancer. Three-year experience with the use of abemaciclib in 64 patients with hormone-dependent, HER2-negative, early breast cancer in real-world practice is analyzed, and the criteria for selecting combination endocrine therapy and the safety profile of treatment escalation are assessed. An indirect comparison of data from the Russian analysis and the randomized clinical monarchE trial of adjuvant endocrine therapy escalation in patients with a high risk of recurrence is conducted. Clinical cases of abemaciclib use in routine practice in Russian patients are presented.
- Open Access
- 5 December 2025
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 27 (3) , 187-197
Following in the footsteps of ASCO-2025: TOP studies that will change the treatment strategy of advanced HR+ and HER2+ breast cancer. A review
This review summarizes the six most significant clinical studies on the treatment of advanced hormone-dependent and HER2-positive (HER2+) breast cancer (BC), presented at the ASCO congress in 2025. Among the new data on overcoming hormone resistance, the assessment of overall survival in patients with early relapses with a PIK3CA gene mutation in the INAVO120 study, the idea of a molecular navigation strategy for switching hormonal treatment when an ESR1 gene mutation appears in the randomized clinical trial SERENA-6, as well as a biomarker analysis of the trastuzumab deruxtecan effectiveness in advanced BC with HER2-low/ultralow expression in the randomized clinical trial DESTINY-Breast06 require special attention. For the treatment of patients with advanced HER2+ BC, an analysis of the efficacy and safety of the combination of trastuzumab deruxtecan with pertuzumab in the first line of treatment, the possibility of reintroducing trastuzumab deruxtecan in case of interstitial pneumonitis, as well as a new direction in the treatment of luminal HER2+ variant using the combination of CDK4/6 inhibitors with anti-HER2 therapy, are addressed.
- 5 December 2025
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 27 (3) , 187-197
Open AccessFollowing in the footsteps of ASCO-2025: TOP studies that will change the treatment strategy of advanced HR+ and HER2+ breast cancer. A review
This review summarizes the six most significant clinical studies on the treatment of advanced hormone-dependent and HER2-positive (HER2+) breast cancer (BC), presented at the ASCO congress in 2025. Among the new data on overcoming hormone resistance, the assessment of overall survival in patients with early relapses with a PIK3CA gene mutation in the INAVO120 study, the idea of a molecular navigation strategy for switching hormonal treatment when an ESR1 gene mutation appears in the randomized clinical trial SERENA-6, as well as a biomarker analysis of the trastuzumab deruxtecan effectiveness in advanced BC with HER2-low/ultralow expression in the randomized clinical trial DESTINY-Breast06 require special attention. For the treatment of patients with advanced HER2+ BC, an analysis of the efficacy and safety of the combination of trastuzumab deruxtecan with pertuzumab in the first line of treatment, the possibility of reintroducing trastuzumab deruxtecan in case of interstitial pneumonitis, as well as a new direction in the treatment of luminal HER2+ variant using the combination of CDK4/6 inhibitors with anti-HER2 therapy, are addressed.
- 8 September 2025
- Published by SAGE Publications in International Journal of Risk & Safety in Medicine
- Vol. 37 (1) , 49-66
An analysis of Russian-produced clinical practice guidelines using the RIGHT reporting checklist: The case of direct oral anticoagulants for coronavirus disease 2019
Objective: The objective of the study was to compare the results of quality assessment of Russian-produced clinical practice guidelines on the use of direct oral anticoagulants in the treatment and prophylaxis of coronavirus disease 2019 using the RIGHT checklist and AGREE II instrument. Methods: We assessed six relevant clinical practice guidelines published between 2020 and 2023 in Russian databases using the RIGHT checklist. We compared the results of using the RIGHT tool with the results obtained using the AGREE II instrument. Results: All six clinical guidelines received high scores in the sections “Basic information” (range: 56.2%–70.8%) and “Background” (48.4%–74.0%). The lowest results were obtained in the sections on RIGHT: “Review and quality assurance” (0%–4.2%) and “Funding and declaration management of interests” (14.6%–19.8%). Conclusion: The RIGHT checklist was proven applicable and usable for evaluating Russian-produced clinical practice guidelines. The use of RIGHT reporting tool enriched the depth and breadth of quality assessment to identify more areas that are problematic and to critically appraise details of the problems. More efforts are needed to further improve Russian clinical practice guidelines and their implementation into clinical practice to ensure better patient care and rational use of direct oral anticoagulants.
- 8 September 2025
- Published by SAGE Publications in International Journal of Risk & Safety in Medicine
- Vol. 37 (1) , 49-66
An analysis of Russian-produced clinical practice guidelines using the RIGHT reporting checklist: The case of direct oral anticoagulants for coronavirus disease 2019
Objective: The objective of the study was to compare the results of quality assessment of Russian-produced clinical practice guidelines on the use of direct oral anticoagulants in the treatment and prophylaxis of coronavirus disease 2019 using the RIGHT checklist and AGREE II instrument. Methods: We assessed six relevant clinical practice guidelines published between 2020 and 2023 in Russian databases using the RIGHT checklist. We compared the results of using the RIGHT tool with the results obtained using the AGREE II instrument. Results: All six clinical guidelines received high scores in the sections “Basic information” (range: 56.2%–70.8%) and “Background” (48.4%–74.0%). The lowest results were obtained in the sections on RIGHT: “Review and quality assurance” (0%–4.2%) and “Funding and declaration management of interests” (14.6%–19.8%). Conclusion: The RIGHT checklist was proven applicable and usable for evaluating Russian-produced clinical practice guidelines. The use of RIGHT reporting tool enriched the depth and breadth of quality assessment to identify more areas that are problematic and to critically appraise details of the problems. More efforts are needed to further improve Russian clinical practice guidelines and their implementation into clinical practice to ensure better patient care and rational use of direct oral anticoagulants.
- Open Access
- 17 July 2025
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 27 (2) , 72-79
Interim results of an multicenter observational clinical study on treatment strategies for chronic lymphocytic leukemia/small lymphocytic lymphoma in Russia
Aim. To evaluate the survival rates in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in routine clinical practice in Russia and to analyze the impact of clinical and demographic factors on therapy selection and treatment outcomes. Materials and methods. An observational study of CLL/SLL treatment strategies has been conducted in 34 centers in Russia from 2021 to the present. Effectiveness was assessed based on survival rates, clinical characteristics, and therapeutic approaches. Statistical analysis included descriptive methods and Kaplan–Meier curves for survival outcomes. Cox proportional hazards models were used to assess the influence of various factors on progression-free survival (PFS). Results. As of the interim analysis (2021–2024), a total of 2,094 patients were included in the study. The majority of the cohort consisted of male patients (54.11%) aged ≥ 65 years (59.8%). Most patients (77.94%) had a favorable performance status of 0–1 according to the ECOG scale. Among molecular-genetic alterations, wild-type TP53 (86.43%) and IGHV (69.27%) were most commonly observed. According to the analysis of treatment data, the most frequently prescribed combinations were FCR (22.32%) and RB (18.67%). In later treatment lines, the proportion of targeted therapies increased. Overall survival among 1654 patients with known treatment start date remained high throughout 10 years of follow-up, and was 93.88% by year 10. Progression-free survival (PFS) was assessed for all patients receiving first-line therapy, including retrospective data. PFS was assessed separately for the second and subsequent lines by type of therapy. PFS among patients who received first-line therapy, regardless of the type of chemotherapy and the presence of TP53/IGHV mutation after 5 years was 76.93%. PFS in the targeted therapy group in patients who received the third, fourth and subsequent lines of therapy was significantly higher than in the immunochemotherapy group (p = 0.001 and 0.009 respectively). According to the Cox model, among patients who received first-line therapy, a significant association of a reduced risk of progression with male gender was shown (HR 0.52, 95% CI 0.33–0.82; p 0.005). There was a trend towards an association of TP53 mutation with a high risk of progression (HR 2.02, 95% CI 0.91–4.51; p = 0.084), but statistical significance was not achieved. In patients who received the third, fourth and subsequent lines of therapy, targeted therapy was significantly associated with a lower risk of progression (HR 0.16, 95% CI 0.05–0.53; p = 0.002 and HR 0.27, 95% CI 0.10–0.75; p = 0.012, respectively). Conclusion. The interim analysis showed generally favorable PFS dynamics, but some subgroups of patients, e.g., those with TP53 mutation, demonstrated a less favorable prognosis. Targeted therapy was significantly associated with a lower risk of disease progression among patients receiving third, fourth, and subsequent lines of therapy. The obtained results confirm the data on the high efficiency of targeted therapy in the treatment of CLL/SLL, especially in patients with an aggressive course of the disease and unfavorable prognostic factors.
- 17 July 2025
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 27 (2) , 72-79
Open AccessInterim results of an multicenter observational clinical study on treatment strategies for chronic lymphocytic leukemia/small lymphocytic lymphoma in Russia
Aim. To evaluate the survival rates in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in routine clinical practice in Russia and to analyze the impact of clinical and demographic factors on therapy selection and treatment outcomes. Materials and methods. An observational study of CLL/SLL treatment strategies has been conducted in 34 centers in Russia from 2021 to the present. Effectiveness was assessed based on survival rates, clinical characteristics, and therapeutic approaches. Statistical analysis included descriptive methods and Kaplan–Meier curves for survival outcomes. Cox proportional hazards models were used to assess the influence of various factors on progression-free survival (PFS). Results. As of the interim analysis (2021–2024), a total of 2,094 patients were included in the study. The majority of the cohort consisted of male patients (54.11%) aged ≥ 65 years (59.8%). Most patients (77.94%) had a favorable performance status of 0–1 according to the ECOG scale. Among molecular-genetic alterations, wild-type TP53 (86.43%) and IGHV (69.27%) were most commonly observed. According to the analysis of treatment data, the most frequently prescribed combinations were FCR (22.32%) and RB (18.67%). In later treatment lines, the proportion of targeted therapies increased. Overall survival among 1654 patients with known treatment start date remained high throughout 10 years of follow-up, and was 93.88% by year 10. Progression-free survival (PFS) was assessed for all patients receiving first-line therapy, including retrospective data. PFS was assessed separately for the second and subsequent lines by type of therapy. PFS among patients who received first-line therapy, regardless of the type of chemotherapy and the presence of TP53/IGHV mutation after 5 years was 76.93%. PFS in the targeted therapy group in patients who received the third, fourth and subsequent lines of therapy was significantly higher than in the immunochemotherapy group (p = 0.001 and 0.009 respectively). According to the Cox model, among patients who received first-line therapy, a significant association of a reduced risk of progression with male gender was shown (HR 0.52, 95% CI 0.33–0.82; p 0.005). There was a trend towards an association of TP53 mutation with a high risk of progression (HR 2.02, 95% CI 0.91–4.51; p = 0.084), but statistical significance was not achieved. In patients who received the third, fourth and subsequent lines of therapy, targeted therapy was significantly associated with a lower risk of progression (HR 0.16, 95% CI 0.05–0.53; p = 0.002 and HR 0.27, 95% CI 0.10–0.75; p = 0.012, respectively). Conclusion. The interim analysis showed generally favorable PFS dynamics, but some subgroups of patients, e.g., those with TP53 mutation, demonstrated a less favorable prognosis. Targeted therapy was significantly associated with a lower risk of disease progression among patients receiving third, fourth, and subsequent lines of therapy. The obtained results confirm the data on the high efficiency of targeted therapy in the treatment of CLL/SLL, especially in patients with an aggressive course of the disease and unfavorable prognostic factors.
- 19 May 2025
- Published by ECO-Vector LLC in Russian Journal of Physiotherapy, Balneology and Rehabilitation
- Vol. 24 (2) , 74-83
The effectiveness of general magnetic therapy and low-frequency electrostatic field: a randomized controlled trial
BACKGROUND: At present, various physical therapy methods have been proposed for the rehabilitation of breast cancer patients. However, a key issue in oncological rehabilitation is that modern protocols often do not take into account functional impairments that arise during combined treatment. Yet minimizing the adverse effects and complications of radical therapy is essential for restoring the function of affected tissues, organs, and systems. AIM: To clarify the mechanisms of action of general magnetotherapy and low-frequency electrostatic field therapy, and to justify their application starting on postoperative days 2–4 in breast cancer patients as part of two consecutive courses of medical rehabilitation. MATERIALS AND METHODS: The study included 78 female patients who underwent surgical treatment for confirmed stage IIB (T2N1M0; T3N0M0) or stage IIIA (T3N1M0; T1–2N2M0) breast cancer. The patients were divided into two groups (main and control) using simple randomization. The groups were comparable in terms of age and clinical and functional indicators, differing only in the prescription of physiotherapeutic methods during the two-stage course of medical rehabilitation. RESULTS: It was established that two courses of medical rehabilitation in breast cancer patients, conducted in the early postoperative period (days 2–4) and again 1–1.5 months after surgery, contributed to the reduction of pain and postoperative edema, improvement in shoulder joint mobility, prevention of severe lymphedema, and enhancement of quality of life. These effects were confirmed by clinical and functional assessments, including laser Doppler flowmetry and electromyographic evaluation of shoulder muscles. Patients in the main group showed better restoration of shoulder joint mobility on the operated side. CONCLUSION: General magnetotherapy exerts a normalizing effect on autonomic and psychoemotional status by selectively modulating hypothalamic excitability in cortical and subcortical brain structures. Low-frequency alternating electrostatic field therapy reduces the formation of protein-rich edema, normalizes neuromuscular excitability, promotes the restoration of tissue elasticity, improves functional tissue condition, and enhances local hemodynamics and microcirculation.
- 19 May 2025
- Published by ECO-Vector LLC in Russian Journal of Physiotherapy, Balneology and Rehabilitation
- Vol. 24 (2) , 74-83
The effectiveness of general magnetic therapy and low-frequency electrostatic field: a randomized controlled trial
BACKGROUND: At present, various physical therapy methods have been proposed for the rehabilitation of breast cancer patients. However, a key issue in oncological rehabilitation is that modern protocols often do not take into account functional impairments that arise during combined treatment. Yet minimizing the adverse effects and complications of radical therapy is essential for restoring the function of affected tissues, organs, and systems. AIM: To clarify the mechanisms of action of general magnetotherapy and low-frequency electrostatic field therapy, and to justify their application starting on postoperative days 2–4 in breast cancer patients as part of two consecutive courses of medical rehabilitation. MATERIALS AND METHODS: The study included 78 female patients who underwent surgical treatment for confirmed stage IIB (T2N1M0; T3N0M0) or stage IIIA (T3N1M0; T1–2N2M0) breast cancer. The patients were divided into two groups (main and control) using simple randomization. The groups were comparable in terms of age and clinical and functional indicators, differing only in the prescription of physiotherapeutic methods during the two-stage course of medical rehabilitation. RESULTS: It was established that two courses of medical rehabilitation in breast cancer patients, conducted in the early postoperative period (days 2–4) and again 1–1.5 months after surgery, contributed to the reduction of pain and postoperative edema, improvement in shoulder joint mobility, prevention of severe lymphedema, and enhancement of quality of life. These effects were confirmed by clinical and functional assessments, including laser Doppler flowmetry and electromyographic evaluation of shoulder muscles. Patients in the main group showed better restoration of shoulder joint mobility on the operated side. CONCLUSION: General magnetotherapy exerts a normalizing effect on autonomic and psychoemotional status by selectively modulating hypothalamic excitability in cortical and subcortical brain structures. Low-frequency alternating electrostatic field therapy reduces the formation of protein-rich edema, normalizes neuromuscular excitability, promotes the restoration of tissue elasticity, improves functional tissue condition, and enhances local hemodynamics and microcirculation.
- Open Access
- 4 May 2025
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 27 (1) , 36-41
Efficacy and safety of immunotherapy for metastatic renal cell carcinoma: A retrospective study
Aim. To evaluate the efficacy and safety of immune checkpoint inhibitors in patients with metastatic renal cell carcinoma (RCC) in the Russian patient population. Materials and methods. This retrospective study included 231 patients (157 males and 74 females) aged 44 to 86 years (median 64.56±8.09) who underwent examination and treatment at Moscow City Hospital named after S.S. Yudin and Moscow Center for Rehabilitation Treatment. Results. The median follow-up was 16.6 months (13.38-18.61). The effectiveness of therapy was evaluated in all patients included in the study. Objective response (complete regression + partial regression) was achieved in 45 (19.5%) patients. Disease control (objective response + stabilization) was reported in 186 (80.5%) subjects. Median of overall survival in patients with metastatic RCC was 15.62 months (95% confidence interval [CI] 12.89-17.75): in the 1st line group, 13.18 months (95% CI 11.21-17.75), and in the 2nd and subsequent lines group, 16.72 months (95% CI 13.41-20.19). Grade 1-2 immune-mediated adverse events were reported in 81.8% (n=189) of patients, of which 97 (78.9%) received 1st line immunotherapy and 92 (85.2%) received 2nd and subsequent lines. Conclusion. RCC immunotherapy in the Russian population is associated with high rates of objective response and disease control in the first line of treatment (19.5 and 80.5%, respectively). This treatment method is typically associated with a small number of grade 3-4 immune-mediated adverse events (3.03% according to our data), which indicates an acceptable safety profile and is comparable with the data from foreign studies.
- 4 May 2025
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 27 (1) , 36-41
Open AccessEfficacy and safety of immunotherapy for metastatic renal cell carcinoma: A retrospective study
Aim. To evaluate the efficacy and safety of immune checkpoint inhibitors in patients with metastatic renal cell carcinoma (RCC) in the Russian patient population. Materials and methods. This retrospective study included 231 patients (157 males and 74 females) aged 44 to 86 years (median 64.56±8.09) who underwent examination and treatment at Moscow City Hospital named after S.S. Yudin and Moscow Center for Rehabilitation Treatment. Results. The median follow-up was 16.6 months (13.38-18.61). The effectiveness of therapy was evaluated in all patients included in the study. Objective response (complete regression + partial regression) was achieved in 45 (19.5%) patients. Disease control (objective response + stabilization) was reported in 186 (80.5%) subjects. Median of overall survival in patients with metastatic RCC was 15.62 months (95% confidence interval [CI] 12.89-17.75): in the 1st line group, 13.18 months (95% CI 11.21-17.75), and in the 2nd and subsequent lines group, 16.72 months (95% CI 13.41-20.19). Grade 1-2 immune-mediated adverse events were reported in 81.8% (n=189) of patients, of which 97 (78.9%) received 1st line immunotherapy and 92 (85.2%) received 2nd and subsequent lines. Conclusion. RCC immunotherapy in the Russian population is associated with high rates of objective response and disease control in the first line of treatment (19.5 and 80.5%, respectively). This treatment method is typically associated with a small number of grade 3-4 immune-mediated adverse events (3.03% according to our data), which indicates an acceptable safety profile and is comparable with the data from foreign studies.